NCT03158064 2026-01-28Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell TumorsMemorial Sloan Kettering Cancer CenterPhase 2 Active not recruiting30 enrolled
NCT04876456 2026-01-15A Phase II Trial of Cabozantinib With Patients With Refractory GCTsIndiana UniversityPhase 2 Active not recruiting50 enrolled
NCT05634785 2026-01-09CD30 CAR for CD30+ NSGCTUNC Lineberger Comprehensive Cancer CenterPhase 2 Completed2 enrolled